Lakefront Biotherapeutics (GLPGF) Deferred Taxes (2017 - 2020)

Lakefront Biotherapeutics (GLPGF) has reported Deferred Taxes for 4 consecutive years, with $370923.5 the latest figure, recorded in Q1 2020.

• On a quarterly basis, Deferred Taxes rose 379.91% year-over-year to $370923.5 in Q1 2020; TTM through Mar 2020 was $4.1 million, a 7.69% increase from a year earlier, with the FY2024 full-year figure at -$245690.8, up 64.6% from the prior year.
• Deferred Taxes was $370923.5 for Q1 2020 at Lakefront Biotherapeutics, up from $77290.8 in the prior quarter.
• Over five years, Deferred Taxes peaked at $163.4 million in Q2 2018 and troughed at -$159.7 million in Q3 2018.
• A 4-year average of -$14.8 million and a median of $76169.0 in 2018 frame the typical range for Deferred Taxes.
• Across the five-year window, Deferred Taxes slumped 48.03% in 2018 and soared 379.91% in 2020, its largest moves.
• Over 4 years, Deferred Taxes stood at -$213115.3 in 2017, then slumped by 74858.33% to -$159.7 million in 2018, then soared by 100.05% to $77290.8 in 2019, then jumped by 379.91% to $370923.5 in 2020.
• The last three Deferred Taxes figures came in at $370923.5 (Q1 2020), $77290.8 (Q1 2019), and -$159.7 million (Q3 2018), per Business Quant data.